DOP2012000138A - Composiciones para tratar nausea y vomito centralmente mediados - Google Patents

Composiciones para tratar nausea y vomito centralmente mediados

Info

Publication number
DOP2012000138A
DOP2012000138A DO2012000138A DO2012000138A DOP2012000138A DO P2012000138 A DOP2012000138 A DO P2012000138A DO 2012000138 A DO2012000138 A DO 2012000138A DO 2012000138 A DO2012000138 A DO 2012000138A DO P2012000138 A DOP2012000138 A DO P2012000138A
Authority
DO
Dominican Republic
Prior art keywords
vomiting
compositions
centrally
medium
treat nausea
Prior art date
Application number
DO2012000138A
Other languages
English (en)
Spanish (es)
Inventor
Riccardo Braglia
Fabio Trento
Sergio Cantoreggi
Roberta Cannella
Daniele Bonadeo
Giorgia Rossi
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43608757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2012000138(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of DOP2012000138A publication Critical patent/DOP2012000138A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Paints Or Removers (AREA)
DO2012000138A 2009-11-18 2012-05-15 Composiciones para tratar nausea y vomito centralmente mediados DOP2012000138A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26247009P 2009-11-18 2009-11-18
US38270910P 2010-09-14 2010-09-14

Publications (1)

Publication Number Publication Date
DOP2012000138A true DOP2012000138A (es) 2012-11-15

Family

ID=43608757

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000138A DOP2012000138A (es) 2009-11-18 2012-05-15 Composiciones para tratar nausea y vomito centralmente mediados

Country Status (40)

Country Link
US (1) US12042494B2 (OSRAM)
EP (3) EP2727590B1 (OSRAM)
JP (1) JP5890780B2 (OSRAM)
KR (1) KR101615108B1 (OSRAM)
CN (6) CN106421793B (OSRAM)
AP (1) AP3083A (OSRAM)
AU (1) AU2010320598B2 (OSRAM)
BR (1) BR112012011485B1 (OSRAM)
CA (1) CA2778301C (OSRAM)
CL (1) CL2012001276A1 (OSRAM)
CO (1) CO6551693A2 (OSRAM)
CR (1) CR20120216A (OSRAM)
CU (1) CU24048B1 (OSRAM)
CY (1) CY1118062T1 (OSRAM)
DK (2) DK2361090T3 (OSRAM)
DO (1) DOP2012000138A (OSRAM)
EA (1) EA026815B1 (OSRAM)
EC (1) ECSP12011907A (OSRAM)
ES (4) ES2494015T3 (OSRAM)
GE (1) GEP20156226B (OSRAM)
GT (1) GT201200156A (OSRAM)
HK (2) HK1214148A1 (OSRAM)
HR (3) HRP20140759T1 (OSRAM)
HU (1) HUE029677T2 (OSRAM)
IL (1) IL219576A (OSRAM)
LT (1) LT2722045T (OSRAM)
MA (1) MA33810B1 (OSRAM)
MX (1) MX2012005347A (OSRAM)
MY (1) MY159393A (OSRAM)
NI (1) NI201200090A (OSRAM)
NZ (1) NZ599439A (OSRAM)
PE (1) PE20121483A1 (OSRAM)
PH (1) PH12012500887A1 (OSRAM)
PL (3) PL2361090T3 (OSRAM)
PT (2) PT2361090E (OSRAM)
RS (2) RS55206B1 (OSRAM)
SI (2) SI2361090T1 (OSRAM)
SM (1) SMT201400112B (OSRAM)
TN (1) TN2012000170A1 (OSRAM)
WO (1) WO2011061622A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
RS55206B1 (sr) 2009-11-18 2017-01-31 Helsinn Healthcare Sa Kompozicije za lečenje centralno posredovane mučnine i povraćanja
US9782397B2 (en) 2011-07-04 2017-10-10 Irbm Science Park S.P.A. Treatment of corneal neovascularization
ES2579616T3 (es) * 2011-10-18 2016-08-12 Helsinn Healthcare Sa Combinaciones terapéuticas de netupitant y palonosetrón
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
CN103520725B (zh) * 2012-07-05 2017-10-24 海思科医药集团股份有限公司 一种治疗呕吐的药物组合物
PT3265087T (pt) 2015-03-04 2020-10-15 Vanda Pharmaceuticals Inc Método de tratamento com tradipitant
CN106902086B (zh) * 2015-12-23 2020-10-20 江苏恒瑞医药股份有限公司 一种包含奈妥匹坦的固体组合物
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN108721214B (zh) * 2017-04-14 2020-06-16 和龙 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
CN108853010A (zh) * 2017-05-15 2018-11-23 和龙 奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途
CN109200018A (zh) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 含有奈妥吡坦的微乳制剂
SI3710000T1 (sl) * 2017-11-17 2025-07-31 Vanda Pharmaceuticals Inc. Tradipitant za uporabo pri zdravljenju gastropareze
CA3089656A1 (en) * 2018-02-02 2019-08-08 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Oral formulations and uses thereof
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4633608A1 (en) 2022-12-12 2025-10-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
AU2023393578A1 (en) 2022-12-12 2025-07-03 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Fixed dose combination comprising netupitant and palonosetron

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU218654B (hu) 1989-11-28 2000-10-28 Syntex (U.S.A.) Inc. Triciklusos vegyületek, ezeket hatóanyagként tartalmazó gyógyászati készítmények és eljárás előállításukra
US5510486A (en) 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US6297395B1 (en) 1995-11-10 2001-10-02 The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Calixarenes and their use for sequestration of metals
DK1035115T3 (da) 1999-02-24 2005-01-24 Hoffmann La Roche 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
IL153834A0 (en) 2000-07-14 2003-07-31 Hoffmann La Roche N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
DK1349541T3 (da) 2000-12-14 2007-01-08 Hoffmann La Roche Selvemulgerende lipidmatrix (SELM)
JP5690461B2 (ja) 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
MY143789A (en) 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
CA2521369A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
RU2007129642A (ru) 2005-02-25 2009-03-27 Ф.Хоффманн-Ля Рош Аг (Ch) Таблетки с улучшенным распределением лекарственного вещества
US7479312B2 (en) 2005-07-07 2009-01-20 Konica Minolta Opto, Inc. Retardation film, polarizing plate, and liquid crystal display device
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
ES2402581T3 (es) * 2006-02-23 2013-05-06 Pfizer Limited Piperidinoilpirrolidinas como agonistas del receptor de melanocortina tipo 4
KR101441459B1 (ko) * 2006-10-24 2014-09-18 헬신 헬쓰케어 에스.에이. 안정성 및 생체이용률이 개선된 염산 팔로노세트론을 포함하는 연질 캡슐
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
CA2709827A1 (en) * 2007-12-18 2009-06-25 Schering Corporation Biomarkers for sensitivity to anti-igf1r therapy
RS55206B1 (sr) 2009-11-18 2017-01-31 Helsinn Healthcare Sa Kompozicije za lečenje centralno posredovane mučnine i povraćanja

Also Published As

Publication number Publication date
AP3083A (en) 2015-01-31
PL2722045T3 (pl) 2017-03-31
CY1118062T1 (el) 2017-06-28
US12042494B2 (en) 2024-07-23
CL2012001276A1 (es) 2012-12-07
ES2595077T3 (es) 2016-12-27
HK1214148A1 (zh) 2016-07-22
CN106421793A (zh) 2017-02-22
PT2722045T (pt) 2016-10-18
IL219576A (en) 2017-08-31
EP2727590B1 (en) 2015-10-21
PH12012500887A1 (en) 2016-08-26
HK1214147A1 (zh) 2016-07-22
HRP20140759T1 (hr) 2014-10-24
AP2012006278A0 (en) 2012-06-30
ES2559475T3 (es) 2016-02-12
PT2361090E (pt) 2014-09-03
NI201200090A (es) 2012-11-13
HUE029677T2 (hu) 2017-03-28
CR20120216A (es) 2012-07-24
CN102655864A (zh) 2012-09-05
EP2722044B1 (en) 2017-01-04
CA2778301A1 (en) 2011-05-26
KR101615108B1 (ko) 2016-05-12
EA026815B1 (ru) 2017-05-31
CN104856998A (zh) 2015-08-26
MA33810B1 (fr) 2012-12-03
EA201290356A1 (ru) 2012-12-28
GEP20156226B (en) 2015-01-26
MX2012005347A (es) 2012-08-03
SMT201400112B (it) 2014-11-10
IL219576A0 (en) 2012-06-28
PE20121483A1 (es) 2012-12-02
EP2727590A1 (en) 2014-05-07
AU2010320598B2 (en) 2016-06-16
CN106421793B (zh) 2023-06-16
PL2361090T3 (pl) 2014-10-31
SI2361090T1 (sl) 2014-09-30
EP2361090A1 (en) 2011-08-31
EP2722044A1 (en) 2014-04-23
CU24048B1 (es) 2014-12-26
ES2623503T3 (es) 2017-07-11
CN107050455B (zh) 2020-09-29
JP2013511507A (ja) 2013-04-04
NZ599439A (en) 2014-06-27
BR112012011485A2 (pt) 2018-04-03
RS53491B1 (sr) 2015-02-27
EP2361090B1 (en) 2014-05-21
CN106512010A (zh) 2017-03-22
PL2722044T3 (pl) 2017-08-31
HRP20170419T1 (hr) 2017-06-02
CN107050455A (zh) 2017-08-18
US20230263799A1 (en) 2023-08-24
MY159393A (en) 2016-12-30
CN104856999A (zh) 2015-08-26
HRP20161277T1 (hr) 2016-11-18
KR20120101456A (ko) 2012-09-13
AU2010320598A1 (en) 2012-06-14
LT2722045T (lt) 2016-09-26
DK2722045T3 (en) 2016-10-24
RS55206B1 (sr) 2017-01-31
SI2722045T1 (sl) 2017-02-28
BR112012011485B1 (pt) 2021-06-29
TN2012000170A1 (en) 2013-12-12
WO2011061622A1 (en) 2011-05-26
ES2494015T3 (es) 2014-09-12
CU20120078A7 (es) 2012-10-15
DK2361090T3 (da) 2014-08-25
JP5890780B2 (ja) 2016-03-22
CO6551693A2 (es) 2012-10-31
GT201200156A (es) 2014-03-27
CA2778301C (en) 2016-06-14
ECSP12011907A (es) 2012-10-30

Similar Documents

Publication Publication Date Title
CO6551693A2 (es) Composiciones para tratar naúseas y vómito centralmente mediados
MX2019008428A (es) Inhibidores de glucosilceramida sintasa.
MX2020002867A (es) Inhibidores de glucosilceramida sintasa.
CR20120202A (es) Métodos y composiciones para tratar cáncer
TR201907783T4 (tr) Benzosulfonamit türevleri, bileşimleri ve kanser hücrelerinin metastazının önlenmesinde kullanımları.
MX379016B (es) Composiciones y metodos para tratar enfermedad de gaucher.
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
DK2252322T3 (da) Vaccinesammensætninger
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
UY32546A (es) Composiciones y metodos para tratar cancer
MX359209B (es) Terapia de combinacion de procaspasa para gliobastoma.
MX389168B (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
CY1115471T1 (el) Συνθεσεις για την αντιμετωπιση της ναυτιας και του εμετου κεντρικης προελευσης
TH149036B (th) การบำบัดรักษาแบบสารรวมซึ่งประกอบรวมด้วยตัวยับยั้ง sglt และตัวยับยั้ง dpp4
TN2013000368A1 (en) Glucosylceramide synthase inhibitors
NI201300052A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
CO6721062A2 (es) Cmposiciones y métodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek
ECSP13012736A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek